ERBB2 and breast carcinoma: In a previous study still, which started in 2019 and is currently in the recruitment phase, (NCT04040686 “HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02”, Phase I,) the safety, dosimetry, and biodistribution of a new single domain antibody were evaluated.